Tag: Anticoagulants
ASA: Intra-Arterial Tenecteplase Beneficial for Large Vessel Occlusion
Improved likelihood of excellent outcome seen with intra-arterial tenecteplase after successful endovascular recanalization
ASA: Alteplase Ups Outcomes at 4.5 to 24 Hours After Symptom Onset in Acute...
Significantly more patients with acute ischemic stroke achieved primary outcome of 0 or 1 on modified Rankin scale at 90 days
Bleeding Risks for Oral Anticoagulants and Aspirin Mostly Similar
Similar risks seen for apixaban and dabigatran versus aspirin, while rates were higher for rivaroxaban
Fewer Bleeding Events Seen With Abelacimab Than Rivaroxaban in A-Fib
Lower levels of free factor XI and fewer bleeding events seen in patients with atrial fibrillation at moderate-to-high risk for stroke
Therapeutic-Dose Anticoagulation Linked to Lower Mortality in COVID-19
Administration of therapeutic- versus prophylactic-dose anticoagulation with heparins linked to lower mortality in patients hospitalized for COVID-19
ASH: Reduced-Dose Anticoagulants Not Noninferior for Recurrent VTE
Noninferiority of reduced-dose anticoagulants could not be proven in patients with VTE who need extended anticoagulation
Bleeding Risk Increased With NSAID Use for VTE Patients Receiving Anticoagulants
More than twofold increased bleeding rate seen with NSAID use for patients treated with oral anticoagulants for VTE
Tenecteplase Has Similar Safety to TPA for Acute Ischemic Stroke
TNK associated with higher likelihood of excellent functional outcome and reduced disability at three months
Early Adoption of DOAC Dashboard Reduces Off-Label Prescribing
Adoption of DOAC population management tool dashboard before July 2018 linked to decline in off-label dosing prescriptions
Oversight of DOAC Prescribing Beneficial for A-Fib, VTE Patients
Oversight identifies errors, especially in a-fib patients, who mainly have alerts for off-label prescribing during follow-up period
